European Urology Open Science最新文献

英文中文

19 Optimizing oncologic outcomes in high-grade non-muscle invasive bladder cancer: Theimpact of a surgeon-led treatment pathway

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00022-9

Scilipoti P., Rosiello G., Viti A., Santangelo A., Briganti A., Moschini M., Montorsi F.

引用次数: 0

8 Novel enhancement of multimodality treatment of prostate cancer, combining radiotherapy,vascular-targeted photodynamic therapy, and immunotherapy

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00039-4

Sjoberg H.T., Macklin S., Philippou Y., Murphy E.A., Tullis I.D.C., Jones K.I., Stribbling S.M., Parkes E.E., Edmondson E.F., Scheiblin D.A., Lockett S.J., Wink D.A., Rittscher J., Preise D., Agemy L., Yechezkel T., Giaccia A., Mills I.G., Muschel R.J., Vojnovic B.,Scherz A., Bryant R.J.

引用次数: 0

2 Studies with high-level evidence can unmask false therapeutic myths: Using the example ofurolithiasis prophylaxis

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00023-0

Roth B., Stritt K., Fuster D.

引用次数: 0

24 Developing new approaches to stress urinary incontinence treatment in women during early phase research into artificial muscle technology

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00028-X

Drake M., Rossiter J., McCarthy A., Garrad M., Faul C.

引用次数: 0

Predicting Urinary Function Outcomes Following Low-dose-rate Brachytherapy for Prostate Cancer 低剂量率前列腺癌近距离放射治疗后泌尿功能预后的预测。

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/j.euros.2024.11.004

Gianni Rüedi , Manolis Pratsinis , Hans-Peter Schmid , Sabine Güsewell , Paul M. Putora , Ludwig Plasswilm , Christoph Schwab , Orlando Burkhardt , Armin Thoeni , Werner Hochreiter , Ladislav Prikler , Stefan Suter , Patrick Stucki , Michael Müntener , Nadja Blick , Hans Schiefer , Gautier Müllhaupt , Daniel S. Engeler

Background and objective

Our aim was to develop a tool using readily available clinical parameters to predict the probability of poor urinary function following low-dose-rate brachytherapy (LDR-BT) for localized prostate cancer.

Methods

Data from the multicentre, prospective Swiss LDR-BT cohort were analyzed for men treated with LDR-BT. Inclusion criteria were minimum follow-up of 3 yr or postoperative treatment with transurethral resection of the prostate (TURP). A total of 914 men were analyzed, with complete data available for 607 men. Pre-interventional variables assessed were International Prostate Symptom Score (IPSS), prostate volume (PV), maximum urinary flow rate, prostate-specific antigen, postvoid residual urine volume, and age. The primary outcome was poor urinary function after LDR-BT, defined as an IPSS-Quality of Life score >3 (“mostly dissatisfied” or worse) at 3 yr or the occurrence of TURP during follow-up. Associations were evaluated using univariable and multivariable logistic regression. Receiver operating characteristic curve analysis was also performed.

Key findings and limitations

Poor urinary function outcomes were observed in 46 patients (5.0%). Significant predictors included pre-interventional IPSS (adjusted odds ratio [aOR] per point 1.18; p < 0.001) and PV (aOR per ml, 1.04; p = 0.004). Limitations of the study include potential selection bias and the absence of external validation.

Conclusions and clinical implications

Pre-interventional IPSS and PV were significant predictors of poor urinary function after LDR-BT for prostate cancer. A risk calculator based on these parameters was developed to assist individualized treatment planning. Further studies are needed to validate these findings before they can be applied in routine clinical practice.

Patient summary

We created a tool to predict the likelihood of urinary problems after a type of radiotherapy called brachytherapy for prostate cancer. The size of the prostate and urinary symptoms before treatment were associated with poor urinary function after treatment. This tool could help doctors and patients in making informed decisions about treatment for prostate cancer.

背景和目的：我们的目的是开发一种工具，使用现成的临床参数来预测局限性前列腺癌低剂量率近距离放射治疗（LDR-BT）后尿功能不良的可能性。方法：来自多中心、前瞻性瑞士LDR-BT队列的数据分析了接受LDR-BT治疗的男性。纳入标准为至少随访3年或术后经尿道前列腺切除术（TURP）。共分析了914名男性，其中607名男性有完整的数据。介入前评估的变量包括国际前列腺症状评分（IPSS）、前列腺体积（PV）、最大尿流率、前列腺特异性抗原、空隙后残留尿量和年龄。主要结局是LDR-BT后的泌尿功能差，定义为3年时ipss生活质量评分bbbb3（“大多数不满意”或更差）或随访期间发生TURP。使用单变量和多变量逻辑回归评估相关性。并进行了受试者工作特征曲线分析。主要发现和局限性：46例患者（5.0%）尿功能不良。显著预测因子包括介入前IPSS(校正优势比[aOR]每点1.18；p = 0.004)。该研究的局限性包括潜在的选择偏倚和缺乏外部验证。结论及临床意义：介入前IPSS和PV是前列腺癌LDR-BT术后尿功能不良的重要预测指标。基于这些参数开发了一个风险计算器，以协助个体化治疗计划。在将这些发现应用于常规临床实践之前，需要进一步的研究来验证这些发现。患者总结：我们创造了一种工具来预测前列腺癌近距离放疗后泌尿系统问题的可能性。治疗前前列腺大小和泌尿系统症状与治疗后泌尿功能不良相关。这个工具可以帮助医生和病人在前列腺癌治疗方面做出明智的决定。

{"title":"Predicting Urinary Function Outcomes Following Low-dose-rate Brachytherapy for Prostate Cancer","authors":"Gianni Rüedi , Manolis Pratsinis , Hans-Peter Schmid , Sabine Güsewell , Paul M. Putora , Ludwig Plasswilm , Christoph Schwab , Orlando Burkhardt , Armin Thoeni , Werner Hochreiter , Ladislav Prikler , Stefan Suter , Patrick Stucki , Michael Müntener , Nadja Blick , Hans Schiefer , Gautier Müllhaupt , Daniel S. Engeler","doi":"10.1016/j.euros.2024.11.004","DOIUrl":"10.1016/j.euros.2024.11.004","url":null,"abstract":"<div><h3>Background and objective</h3><div>Our aim was to develop a tool using readily available clinical parameters to predict the probability of poor urinary function following low-dose-rate brachytherapy (LDR-BT) for localized prostate cancer.</div></div><div><h3>Methods</h3><div>Data from the multicentre, prospective Swiss LDR-BT cohort were analyzed for men treated with LDR-BT. Inclusion criteria were minimum follow-up of 3 yr or postoperative treatment with transurethral resection of the prostate (TURP). A total of 914 men were analyzed, with complete data available for 607 men. Pre-interventional variables assessed were International Prostate Symptom Score (IPSS), prostate volume (PV), maximum urinary flow rate, prostate-specific antigen, postvoid residual urine volume, and age. The primary outcome was poor urinary function after LDR-BT, defined as an IPSS-Quality of Life score >3 (“mostly dissatisfied” or worse) at 3 yr or the occurrence of TURP during follow-up. Associations were evaluated using univariable and multivariable logistic regression. Receiver operating characteristic curve analysis was also performed.</div></div><div><h3>Key findings and limitations</h3><div>Poor urinary function outcomes were observed in 46 patients (5.0%). Significant predictors included pre-interventional IPSS (adjusted odds ratio [aOR] per point 1.18; <em>p</em> < 0.001) and PV (aOR per ml, 1.04; <em>p</em> = 0.004). Limitations of the study include potential selection bias and the absence of external validation.</div></div><div><h3>Conclusions and clinical implications</h3><div>Pre-interventional IPSS and PV were significant predictors of poor urinary function after LDR-BT for prostate cancer. A risk calculator based on these parameters was developed to assist individualized treatment planning. Further studies are needed to validate these findings before they can be applied in routine clinical practice.</div></div><div><h3>Patient summary</h3><div>We created a tool to predict the likelihood of urinary problems after a type of radiotherapy called brachytherapy for prostate cancer. The size of the prostate and urinary symptoms before treatment were associated with poor urinary function after treatment. This tool could help doctors and patients in making informed decisions about treatment for prostate cancer.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 31-37"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

6 Survival results of PSMA/PET-based salvage radiotherapy for recurrent prostate cancer

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00037-0

Grivas N., van Leeuwen P., Wit E., Vis A., Nieuwenhuijzen J., Pos F., van der Poel H.

引用次数: 0

18 The role of PSMA expression in predicting aggressive disease phenotypes in patients with prostate cancer

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00021-7

Gandaglia G., Scuderi S., Barletta F., Stabile A., Cucchiara V., Montorsi F., Briganti A.

引用次数: 0

12 Predicting pathological tumor volume in prostate cancer lesions using micro-ultrasound and MRI

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/S2666-1683(25)00015-1

Rakauskas A., Richmond A., La Rosa S., Vietti-Violi N., Valerio M.

引用次数: 0

Preoperative Physical Activity Improvement with the Use of Activity Trackers in Patients Undergoing Radical Cystectomy—A Bicentric, Open-label, Randomised Controlled Trial: A Clinical Study Protocol of the PreAct Trial 使用活动追踪器改善根治性膀胱切除术患者的术前身体活动——一项双中心、开放标签、随机对照试验：PreAct试验的临床研究方案

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/j.euros.2024.11.003

Johannes Hermann Kilz , Marie Angela Sidoti Abate , Victoria Luise Simone Wieland , Luisa Egen , Caelan Max Haney , Aleksander Antoniewicz , Alexander Studier-Fischer , Thomas Stefan Worst , Maurice Stephan Michel , Patrick Honeck , Niklas Westhoff , Maximilian Christian Kriegmair , Karl-Friedrich Kowalewski

引用次数: 0

Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer 磁共振成像引导下经尿道补救性超声消融治疗局限性放射性复发性前列腺癌。

IF 3.2 3区医学 Q1 UROLOGY & NEPHROLOGY

European Urology Open Science

Pub Date : 2025-01-01 DOI: 10.1016/j.euros.2024.11.001

Mikael Anttinen , Pietari Mäkelä , Pertti Nurminen , Heikki Pärssinen , Simona Malaspina , Teija Sainio , Mikael Högerman , Pekka Taimen , Roberto Blanco Sequeiros , Peter J. Boström

Background and objective

Toxicity from local salvage therapy for radiorecurrent prostate cancer (PCa) remains a concern. This phase 2 study evaluates the outcomes of salvage magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (sTULSA).

Methods

Men with biochemically relapsed, biopsy-proven PCa following definitive radiotherapy underwent whole- or partial-gland sTULSA (NCT03350529). Prostate-confined recurrence was confirmed by MRI and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT). The primary endpoints were safety (Clavien-Dindo classification) and efficacy (prostate-specific antigen [PSA], PSMA PET-CT, and MRI-targeted biopsy at 12 mo). The secondary endpoints included functional and survival outcomes.

Key findings and limitations

Thirty-nine patients underwent sTULSA (64% whole gland), with a median age of 73 yr (interquartile range [IQR]: 69–77) and PSA of 3.3 ng/ml (IQR: 2–6.2). Three patients had undergone prior salvage therapy, 16 were receiving hormonal therapy at enrollment, and 12 had a history of transurethral interventions. Eighteen patients had incidental urethral strictures on baseline cystoscopy. Over a median follow-up of 40 mo (IQR: 24–55), 56% experienced adverse events. Severe genitourinary toxicity (Clavien-Dindo ≥3 or hospitalization) occurred in 28%, including three patients with puboprostatic fistulas and two patients requiring cystectomy. Leak-free continence was maintained in 53%. At 12 mo, 89% showed no cancer in the targeted area, with a median PSA reduction of 95% (p < 0.001). Five-year metastasis-free, failure-free, and biochemical recurrence–free survival probabilities (95% confidence interval) were 97% (0.93–1.00), 70% (0.54–0.91), and 54% (0.31–0.93), respectively. Limitations included single-arm design and moderate sample size.

Conclusions and clinical implications

It has been observed that sTULSA is effective for radiorecurrent PCa, although genitourinary toxicity remains a concern. Further studies should refine patient selection and treatment parameters to improve safety and tolerability.

Patient summary

In this study, we examined a new treatment called magnetic resonance imaging–guided transurethral ultrasound ablation for prostate cancer that has returned after radiation therapy. We found that the treatment provided effective and lasting cancer control for most patients. However, a notable number of patients experienced significant genitourinary toxicity, including severe adverse effects affecting urinary function. Careful patient selection is crucial to minimize these adverse effects and ensure the best results.

背景和目的：放射复发性前列腺癌（PCa）局部挽救治疗的毒性仍然是一个值得关注的问题。这项2期研究评估了补救性磁共振成像（MRI）引导下经尿道超声消融（sTULSA）的结果。方法：确诊放射治疗后生化复发、活检证实的前列腺癌患者行全腺体或部分腺体sTULSA （NCT03350529）。通过MRI、前列腺特异性膜抗原（PSMA）、正电子发射断层扫描（PET）、计算机断层扫描（CT）证实前列腺局限性复发。主要终点是安全性（Clavien-Dindo分级）和有效性（前列腺特异性抗原[PSA]、PSMA PET-CT和12月mri靶向活检）。次要终点包括功能和生存结局。主要发现和局限性：39例患者接受了sTULSA（64%全腺体），中位年龄为73岁（四分位数范围[IQR]: 69-77）， PSA为3.3 ng/ml （IQR: 2-6.2）。3例患者既往接受过挽救性治疗，16例患者入组时正在接受激素治疗，12例患者有经尿道干预史。基线膀胱镜检查有18例偶发尿道狭窄。中位随访40个月（IQR: 24-55）， 56%的患者出现不良事件。28%的患者发生了严重的泌尿生殖系统毒性（Clavien-Dindo≥3或住院），包括3例耻骨前列腺瘘患者和2例需要膀胱切除术的患者。53%的患者保持无渗漏尿失禁。12个月时，89%的患者在靶区未发现癌症，PSA中位数降低了95% (p)结论和临床意义：已经观察到sTULSA对放射复发性PCa有效，尽管泌尿生殖系统毒性仍然值得关注。进一步的研究应完善患者选择和治疗参数，以提高安全性和耐受性。患者总结：在这项研究中，我们研究了一种新的治疗方法，称为磁共振成像引导经尿道超声消融治疗放射治疗后复发的前列腺癌。我们发现这种治疗方法对大多数患者提供了有效和持久的癌症控制。然而，相当数量的患者出现了明显的泌尿生殖系统毒性，包括影响泌尿功能的严重不良反应。仔细的患者选择是至关重要的，以尽量减少这些不良反应，并确保最好的结果。

{"title":"Salvage Magnetic Resonance Imaging–guided Transurethral Ultrasound Ablation for Localized Radiorecurrent Prostate Cancer","authors":"Mikael Anttinen , Pietari Mäkelä , Pertti Nurminen , Heikki Pärssinen , Simona Malaspina , Teija Sainio , Mikael Högerman , Pekka Taimen , Roberto Blanco Sequeiros , Peter J. Boström","doi":"10.1016/j.euros.2024.11.001","DOIUrl":"10.1016/j.euros.2024.11.001","url":null,"abstract":"<div><h3>Background and objective</h3><div>Toxicity from local salvage therapy for radiorecurrent prostate cancer (PCa) remains a concern. This phase 2 study evaluates the outcomes of salvage magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (sTULSA).</div></div><div><h3>Methods</h3><div>Men with biochemically relapsed, biopsy-proven PCa following definitive radiotherapy underwent whole- or partial-gland sTULSA (NCT03350529). Prostate-confined recurrence was confirmed by MRI and prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT). The primary endpoints were safety (Clavien-Dindo classification) and efficacy (prostate-specific antigen [PSA], PSMA PET-CT, and MRI-targeted biopsy at 12 mo). The secondary endpoints included functional and survival outcomes.</div></div><div><h3>Key findings and limitations</h3><div>Thirty-nine patients underwent sTULSA (64% whole gland), with a median age of 73 yr (interquartile range [IQR]: 69–77) and PSA of 3.3 ng/ml (IQR: 2–6.2). Three patients had undergone prior salvage therapy, 16 were receiving hormonal therapy at enrollment, and 12 had a history of transurethral interventions. Eighteen patients had incidental urethral strictures on baseline cystoscopy. Over a median follow-up of 40 mo (IQR: 24–55), 56% experienced adverse events. Severe genitourinary toxicity (Clavien-Dindo ≥3 or hospitalization) occurred in 28%, including three patients with puboprostatic fistulas and two patients requiring cystectomy. Leak-free continence was maintained in 53%. At 12 mo, 89% showed no cancer in the targeted area, with a median PSA reduction of 95% (<em>p</em> < 0.001). Five-year metastasis-free, failure-free, and biochemical recurrence–free survival probabilities (95% confidence interval) were 97% (0.93–1.00), 70% (0.54–0.91), and 54% (0.31–0.93), respectively. Limitations included single-arm design and moderate sample size.</div></div><div><h3>Conclusions and clinical implications</h3><div>It has been observed that sTULSA is effective for radiorecurrent PCa, although genitourinary toxicity remains a concern. Further studies should refine patient selection and treatment parameters to improve safety and tolerability.</div></div><div><h3>Patient summary</h3><div>In this study, we examined a new treatment called magnetic resonance imaging–guided transurethral ultrasound ablation for prostate cancer that has returned after radiation therapy. We found that the treatment provided effective and lasting cancer control for most patients. However, a notable number of patients experienced significant genitourinary toxicity, including severe adverse effects affecting urinary function. Careful patient selection is crucial to minimize these adverse effects and ensure the best results.</div></div>","PeriodicalId":12254,"journal":{"name":"European Urology Open Science","volume":"71 ","pages":"Pages 69-77"},"PeriodicalIF":3.2,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

European Urology Open Science

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀